TPD52L2 and prostate carcinoma: In addition, TPD52L2 was also reported to regulate proliferation, apoptosis, and vehicle trafficking in a variety of tumors, including glioma (Wang et al., 2014), pancreatic adenocarcinoma (Chen et al., 2017), prostate cancer (Ren et al., 2017; Chi et al., 2018), and glioblastoma (Qiang et al., 2018).